朱列玉:推动设立医强险解决医疗纠纷

2016-03-04 新华社 新华社

今天(3月4日),全国人大代表、广东国鼎律师事务所主任朱列玉作客南方传媒集团全国两会嘉宾访谈室,聊聊他的议案、建议。他表示,在医疗纠纷方面,设立医强险是个很好的解决办法。主持人:请问您今年比较关注的领域是什么?最想推动是什么?朱列玉:首先我想推动的是医强险。在医疗纠纷方面,我觉得有一个很好的办法,就是设立医强险。医疗责任事故国家一直主张用保险来解决,但是很难推动,因为商业保险没有强制性,现在全国买

今天(3月4日),全国人大代表、广东国鼎律师事务所主任朱列玉作客南方传媒集团全国两会嘉宾访谈室,聊聊他的议案、建议。他表示,在医疗纠纷方面,设立医强险是个很好的解决办法。

主持人:请问您今年比较关注的领域是什么?最想推动是什么?

朱列玉:首先我想推动的是医强险。在医疗纠纷方面,我觉得有一个很好的办法,就是设立医强险。医疗责任事故国家一直主张用保险来解决,但是很难推动,因为商业保险没有强制性,现在全国买了责任保险的医院只有7%到8%。交通责任事故发生之后,纠纷相对比较少,因为大家都买了交强险,有什么问题保险公司去谈。如果医疗责任事故有了医强险,就不一样了,是医院的责任就医院赔,不是医院的责任就保险公司赔,有了医疗纠纷就不是患者跟医院去吵架,而是变成保险公司跟医院去交涉。

在医疗纠纷中,患者是一个弱势群体,普通老百姓不懂医学知识、取证,如果换成保险公司就不一样了,保险公司变成患者利益的代表,他可以聘请很多专家,这样患者家属更容易信服,医闹就没有了市场。医患纠纷就可以得到解决,所以我建议要推动医强险。这个强制保险的保费,可以多方都出一点,比如医院、患者、国家,这个问题就可以得到解决。

主持人:您还提出了在“一带一路”的建设中推动建立国际民商事仲裁院?

朱列玉:对,现在我们国家的仲裁主要是国际经济贸易仲裁委员会,国家级的就这么一个仲裁院,地方仲裁院涉外的不多,比如广州仲裁委员会主要是处理国内的民商事纠纷,涉外的有一点,但是不多。在“一带一路”建设中会牵涉到不同国家民商法的冲突,如果有一个针对“一带一路”的国际民商仲裁院应该非常好,可以调节不同国家之间的民商事的纠纷,也可以做一些法规的整理工作,形成一些在“一带一路”大家共同遵守的民商事规则,把依法治国的理念贯彻到“一带一路”的建设中去。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=67484, encodeId=a8296e484f8, content=必须解决基本问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Sun Mar 06 09:52:00 CST 2016, time=2016-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402103, encodeId=4cfa140210340, content=<a href='/topic/show?id=310a35124e9' target=_blank style='color:#2F92EE;'>#医疗纠纷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35124, encryptionId=310a35124e9, topicName=医疗纠纷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f6f2387781, createdName=yyanpro@22cn.c, createdTime=Sun Mar 06 07:59:00 CST 2016, time=2016-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536371, encodeId=862015363e137, content=<a href='/topic/show?id=c054e70973c' target=_blank style='color:#2F92EE;'>#纠纷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77097, encryptionId=c054e70973c, topicName=纠纷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74d012693594, createdName=ewsr5, createdTime=Sun Mar 06 07:59:00 CST 2016, time=2016-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67340, encodeId=35ac6e340bb, content=关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160305/IMG56D9B397BC9D76610.jpg, createdBy=2a9c1696163, createdName=GHC8095, createdTime=Sat Mar 05 13:50:00 CST 2016, time=2016-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67256, encodeId=d87e6e25687, content=关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24721662825, createdName=1ddf23d5m57(暂无匿称), createdTime=Sat Mar 05 07:49:00 CST 2016, time=2016-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67202, encodeId=f8016e202bf, content=关注一下这个问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3bd31668701, createdName=1de07360m07(暂无匿称), createdTime=Fri Mar 04 17:23:00 CST 2016, time=2016-03-04, status=1, ipAttribution=)]
    2016-03-06 老段

    必须解决基本问题

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=67484, encodeId=a8296e484f8, content=必须解决基本问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Sun Mar 06 09:52:00 CST 2016, time=2016-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402103, encodeId=4cfa140210340, content=<a href='/topic/show?id=310a35124e9' target=_blank style='color:#2F92EE;'>#医疗纠纷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35124, encryptionId=310a35124e9, topicName=医疗纠纷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f6f2387781, createdName=yyanpro@22cn.c, createdTime=Sun Mar 06 07:59:00 CST 2016, time=2016-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536371, encodeId=862015363e137, content=<a href='/topic/show?id=c054e70973c' target=_blank style='color:#2F92EE;'>#纠纷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77097, encryptionId=c054e70973c, topicName=纠纷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74d012693594, createdName=ewsr5, createdTime=Sun Mar 06 07:59:00 CST 2016, time=2016-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67340, encodeId=35ac6e340bb, content=关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160305/IMG56D9B397BC9D76610.jpg, createdBy=2a9c1696163, createdName=GHC8095, createdTime=Sat Mar 05 13:50:00 CST 2016, time=2016-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67256, encodeId=d87e6e25687, content=关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24721662825, createdName=1ddf23d5m57(暂无匿称), createdTime=Sat Mar 05 07:49:00 CST 2016, time=2016-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67202, encodeId=f8016e202bf, content=关注一下这个问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3bd31668701, createdName=1de07360m07(暂无匿称), createdTime=Fri Mar 04 17:23:00 CST 2016, time=2016-03-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=67484, encodeId=a8296e484f8, content=必须解决基本问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Sun Mar 06 09:52:00 CST 2016, time=2016-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402103, encodeId=4cfa140210340, content=<a href='/topic/show?id=310a35124e9' target=_blank style='color:#2F92EE;'>#医疗纠纷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35124, encryptionId=310a35124e9, topicName=医疗纠纷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f6f2387781, createdName=yyanpro@22cn.c, createdTime=Sun Mar 06 07:59:00 CST 2016, time=2016-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536371, encodeId=862015363e137, content=<a href='/topic/show?id=c054e70973c' target=_blank style='color:#2F92EE;'>#纠纷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77097, encryptionId=c054e70973c, topicName=纠纷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74d012693594, createdName=ewsr5, createdTime=Sun Mar 06 07:59:00 CST 2016, time=2016-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67340, encodeId=35ac6e340bb, content=关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160305/IMG56D9B397BC9D76610.jpg, createdBy=2a9c1696163, createdName=GHC8095, createdTime=Sat Mar 05 13:50:00 CST 2016, time=2016-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67256, encodeId=d87e6e25687, content=关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24721662825, createdName=1ddf23d5m57(暂无匿称), createdTime=Sat Mar 05 07:49:00 CST 2016, time=2016-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67202, encodeId=f8016e202bf, content=关注一下这个问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3bd31668701, createdName=1de07360m07(暂无匿称), createdTime=Fri Mar 04 17:23:00 CST 2016, time=2016-03-04, status=1, ipAttribution=)]
    2016-03-06 ewsr5
  4. [GetPortalCommentsPageByObjectIdResponse(id=67484, encodeId=a8296e484f8, content=必须解决基本问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Sun Mar 06 09:52:00 CST 2016, time=2016-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402103, encodeId=4cfa140210340, content=<a href='/topic/show?id=310a35124e9' target=_blank style='color:#2F92EE;'>#医疗纠纷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35124, encryptionId=310a35124e9, topicName=医疗纠纷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f6f2387781, createdName=yyanpro@22cn.c, createdTime=Sun Mar 06 07:59:00 CST 2016, time=2016-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536371, encodeId=862015363e137, content=<a href='/topic/show?id=c054e70973c' target=_blank style='color:#2F92EE;'>#纠纷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77097, encryptionId=c054e70973c, topicName=纠纷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74d012693594, createdName=ewsr5, createdTime=Sun Mar 06 07:59:00 CST 2016, time=2016-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67340, encodeId=35ac6e340bb, content=关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160305/IMG56D9B397BC9D76610.jpg, createdBy=2a9c1696163, createdName=GHC8095, createdTime=Sat Mar 05 13:50:00 CST 2016, time=2016-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67256, encodeId=d87e6e25687, content=关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24721662825, createdName=1ddf23d5m57(暂无匿称), createdTime=Sat Mar 05 07:49:00 CST 2016, time=2016-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67202, encodeId=f8016e202bf, content=关注一下这个问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3bd31668701, createdName=1de07360m07(暂无匿称), createdTime=Fri Mar 04 17:23:00 CST 2016, time=2016-03-04, status=1, ipAttribution=)]
    2016-03-05 GHC8095

    关注

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=67484, encodeId=a8296e484f8, content=必须解决基本问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Sun Mar 06 09:52:00 CST 2016, time=2016-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402103, encodeId=4cfa140210340, content=<a href='/topic/show?id=310a35124e9' target=_blank style='color:#2F92EE;'>#医疗纠纷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35124, encryptionId=310a35124e9, topicName=医疗纠纷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f6f2387781, createdName=yyanpro@22cn.c, createdTime=Sun Mar 06 07:59:00 CST 2016, time=2016-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536371, encodeId=862015363e137, content=<a href='/topic/show?id=c054e70973c' target=_blank style='color:#2F92EE;'>#纠纷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77097, encryptionId=c054e70973c, topicName=纠纷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74d012693594, createdName=ewsr5, createdTime=Sun Mar 06 07:59:00 CST 2016, time=2016-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67340, encodeId=35ac6e340bb, content=关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160305/IMG56D9B397BC9D76610.jpg, createdBy=2a9c1696163, createdName=GHC8095, createdTime=Sat Mar 05 13:50:00 CST 2016, time=2016-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67256, encodeId=d87e6e25687, content=关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24721662825, createdName=1ddf23d5m57(暂无匿称), createdTime=Sat Mar 05 07:49:00 CST 2016, time=2016-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67202, encodeId=f8016e202bf, content=关注一下这个问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3bd31668701, createdName=1de07360m07(暂无匿称), createdTime=Fri Mar 04 17:23:00 CST 2016, time=2016-03-04, status=1, ipAttribution=)]
    2016-03-05 1ddf23d5m57(暂无匿称)

    关注

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=67484, encodeId=a8296e484f8, content=必须解决基本问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Sun Mar 06 09:52:00 CST 2016, time=2016-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402103, encodeId=4cfa140210340, content=<a href='/topic/show?id=310a35124e9' target=_blank style='color:#2F92EE;'>#医疗纠纷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35124, encryptionId=310a35124e9, topicName=医疗纠纷)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f6f2387781, createdName=yyanpro@22cn.c, createdTime=Sun Mar 06 07:59:00 CST 2016, time=2016-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536371, encodeId=862015363e137, content=<a href='/topic/show?id=c054e70973c' target=_blank style='color:#2F92EE;'>#纠纷#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77097, encryptionId=c054e70973c, topicName=纠纷)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74d012693594, createdName=ewsr5, createdTime=Sun Mar 06 07:59:00 CST 2016, time=2016-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67340, encodeId=35ac6e340bb, content=关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160305/IMG56D9B397BC9D76610.jpg, createdBy=2a9c1696163, createdName=GHC8095, createdTime=Sat Mar 05 13:50:00 CST 2016, time=2016-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67256, encodeId=d87e6e25687, content=关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24721662825, createdName=1ddf23d5m57(暂无匿称), createdTime=Sat Mar 05 07:49:00 CST 2016, time=2016-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=67202, encodeId=f8016e202bf, content=关注一下这个问题, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3bd31668701, createdName=1de07360m07(暂无匿称), createdTime=Fri Mar 04 17:23:00 CST 2016, time=2016-03-04, status=1, ipAttribution=)]
    2016-03-04 1de07360m07(暂无匿称)

    关注一下这个问题

    0

相关资讯

从Oscar的崛起看奥巴马医改给美国医疗保险市场带来的变化

Oscar是纽约州一家古怪的创业医疗保险公司,他们希望能够改变这种现状。公司的网站非常人性化,用户填完自己的症状后系统就会为其推荐医疗卫生服务提供者。用户还可以向医生进行在线咨询,而这项全天候的服务是免费的。 在他们的网站上,用户可以对比不同医疗卫生服务提供者的价格,还可以一键式补充处方药。该公司甚至与CVS达成了合作,在纽约州全境建立了多家护理中心。另外他们还雇佣了很多护士,为患者